Literature DB >> 8396818

Coincident involvement of flvi-2, c-myc, and novel env genes in natural and experimental lymphosarcomas induced by feline leukemia virus.

L S Levy1, P A Lobelle-Rich, J Overbaugh, J L Abkowitz, R Fulton, P Roy-Burman.   

Abstract

The flvi-2 locus is a target of insertional mutagenesis in thymic lymphosarcomas induced by feline leukemia virus (FeLV). flvi-2 encodes the gene bmi-1, whose product is implicated as a myc-collaborator in the induction of B- and T-cell lymphoma. We have examined the involvement of flvi-2 and myc in natural and experimentally induced FeLV-positive feline lymphosarcomas which are heterogeneous in anatomical origin, geographic origin, and strain of FeLV involved. We further compared these findings with previous reports of novel FeLV env genes in the same tumors. The results show that proviral insertion at flvi-2 occurs commonly in natural and experimental feline thymic lymphosarcomas of diverse origins [52% overall], and that alterations in c-myc commonly accompany insertional mutagenesis of flvi-2 [54% overall]. However, 46% of tumors with flvi-2 insertions apparently lack involvement of c-myc. These observations support the hypothesis that interruption of flvi-2 may be an early event in a multistep cascade, one possibility for completion of which is activation of c-myc. Interruption of flvi-2 was not observed in nonthymic lymphosarcomas of alimentary or multicentric origin, although c-myc may be involved. A proportion of both thymic and nonthymic tumors have been shown previously to contain FeLV proviruses with recombinant or mutant env genes. Our findings strongly implicate the insertional mutagenesis of flvi-2, the activation of c-myc, and the emergence of novel env genes in FeLV-mediated lymphomagenesis, particularly in the induction of thymic lymphosarcoma. The data show that these events may overlap, but do not necessarily occur concurrently.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396818     DOI: 10.1006/viro.1993.1553

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  A novel truncated env gene isolated from a feline leukemia virus-induced thymic lymphosarcoma.

Authors:  Y Shi; P Roy-Burman
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Transduction of Notch2 in feline leukemia virus-induced thymic lymphoma.

Authors:  J L Rohn; A S Lauring; M L Linenberger; J Overbaugh
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Characterization of pal-1, a common proviral insertion site in murine leukemia virus-induced lymphomas of c-myc and Pim-1 transgenic mice.

Authors:  B Scheijen; J Jonkers; D Acton; A Berns
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  In vivo evolution of a novel, syncytium-inducing and cytopathic feline leukemia virus variant.

Authors:  J L Rohn; M S Moser; S R Gwynn; D N Baldwin; J Overbaugh
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

5.  Genetic determinants of feline leukemia virus-induced lymphoid tumors: patterns of proviral insertion and gene rearrangement.

Authors:  C Tsatsanis; R Fulton; K Nishigaki; H Tsujimoto; L Levy; A Terry; D Spandidos; D Onions; J C Neil
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

Review 6.  Endogenous env elements: partners in generation of pathogenic feline leukemia viruses.

Authors:  P Roy-Burman
Journal:  Virus Genes       Date:  1995       Impact factor: 2.332

Review 7.  Viral determinants of FeLV infection and pathogenesis: lessons learned from analysis of a natural cohort.

Authors:  Lisa L Bolin; Laura S Levy
Journal:  Viruses       Date:  2011-09-09       Impact factor: 5.048

Review 8.  Infectious Causes of Neoplasia in the Domestic Cat.

Authors:  Kerry E Rolph; Ryan P Cavanaugh
Journal:  Vet Sci       Date:  2022-08-30

Review 9.  Haematological disorders associated with feline retrovirus infections.

Authors:  M L Linenberger; J L Abkowitz
Journal:  Baillieres Clin Haematol       Date:  1995-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.